Drug Profile


Alternative Names: amiloride hydrochloride plus spironolactone; HTI-101

Latest Information Update: 03 Aug 2015

Price : $50

At a glance

  • Originator University of Alabama
  • Class Antihormones; Antihypertensives; Lactones; Pregnenes; Pyrazines; Small molecules
  • Mechanism of Action Aldosterone antagonists; Potassium-sparing diuretics; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Resistant hypertension

Most Recent Events

  • 03 Aug 2015 No recent reports on development identified - Phase-II for Resistant hypertension in USA (PO)
  • 14 Dec 2009 HTI 101 is available for collaboration for development and commercialisation (
  • 08 Dec 2009 Phase-II clinical trials in Resistant hypertension in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top